Core Laboratories N.V. (CLB)
NYSE: CLB
· Real-Time Price · USD
11.68
-0.12 (-1.02%)
At close: Jun 27, 2025, 3:29 PM
Core Laboratories Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
| Product Revenue | 135.64M | 137.88M |
| Product Revenue Growth | -1.62% | n/a |
| Service Revenue | 388.2M | 371.91M |
| Service Revenue Growth | +4.38% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Countries Revenue | 344.95M | 331.24M | 323.03M | 322.07M | 328.33M | 353.8M | 342.14M | 342.53M | 347.33M | 414.81M | 464.33M | 445.57M | 374.49M | 351.76M |
| Other Countries Revenue Growth | +4.14% | +2.54% | +0.30% | -1.91% | -7.20% | +3.41% | -0.11% | -1.38% | -16.27% | -10.67% | +4.21% | +18.98% | +6.46% | n/a |
| United States Revenue | 178.9M | 178.55M | 166.7M | 148.18M | 158.94M | 289.17M | 324.07M | 284.26M | 224.86M | 338.91M | 515.64M | n/a | n/a | n/a |
| United States Revenue Growth | +0.19% | +7.11% | +12.50% | -6.77% | -45.04% | -10.77% | +14.01% | +26.41% | -33.65% | -34.27% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 13.65M | 9.08M | 8.33M | 10.26M | 11.79M | 8.66M | 9.45M | 5.81M | 16.33M | 8.72M | 10M | 6.85M | 12.54M | 10.93M | 15.12M | 9.67M | 8.46M | -3.69M | 8.94M | 9.22M | 19.57M | 9.77M | 11.01M | 9.8M | 17.44M | 24.72M | 13.28M | 12.2M | 12.71M | 11.99M | 11.89M | 11.1M | 12.76M | 8.79M | 8.41M | 11.14M | 11.05M | 12.27M | 12.15M | 12.63M | 12.67M |
| Selling, General, and Administrative Revenue Growth | +50.30% | +9.03% | -18.82% | -12.98% | +36.05% | -8.33% | +62.66% | -64.42% | +87.20% | -12.77% | +46.06% | -45.42% | +14.81% | -27.71% | +56.31% | +14.29% | -329.17% | -141.31% | -3.08% | -52.87% | +100.21% | -11.25% | +12.36% | -43.79% | -29.46% | +86.18% | +8.82% | -3.99% | +5.96% | +0.90% | +7.09% | -12.98% | +45.04% | +4.63% | -24.54% | +0.81% | -9.91% | +0.91% | -3.79% | -0.32% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |